se of high flow nasal cannula in Covid 19 patients with respiratory failure
Phase 4
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/04/032795
- Lead Sponsor
- Government Medical College Vadodara
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
COVID â?? 19 pneumonia (Diagnosed with polymerase chain reaction)
Age more than 18 years of either gender
Acute Hypoxemic Respiratory Failure
Admission to intensive care unit
Supported by high flow nasal cannulae
Exclusion Criteria
Intubation prior to HFNC therapy
Uncooperative and neurologically (Glasgow coma scale less than equal to 12) unstable patients
Patients with haemodynamic instability
Patients with primary pulmonary disease, respiratory acidosis in the first blood gases (pH < 7.2,pCO2 >= 50)
In all conditions where PEEP is contraindicated like in presence of pneumothorax, large bullae in lungs or haemodynamic instability.
Patient not accepting nasal cannula due to irritation or discomfort
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To describe the use of HFNC in COVID â?? 19 patients with acute hypoxemic respiratory failure and evaluation of ROX index over time in patients treated with HFNC.Timepoint: 6 months or cessation of COVID 19 pandemic whichever is earlier
- Secondary Outcome Measures
Name Time Method 1)Requirement of HFNC flow <br/ ><br>2)Requirement of FiO2 <br/ ><br>3)Respiratory rate during HFNC therapy <br/ ><br>4)Success rate of using HFNC <br/ ><br> <br/ ><br>Timepoint: 6 months or cessation of COVID 19 pandemic whichever is earlier